Shanghai Haohai Biological Technology Co Ltd banner

Shanghai Haohai Biological Technology Co Ltd
SSE:688366

Watchlist Manager
Shanghai Haohai Biological Technology Co Ltd Logo
Shanghai Haohai Biological Technology Co Ltd
SSE:688366
Watchlist
Price: 39.65 CNY -0.08% Market Closed
Market Cap: ¥9.1B

P/FCFE

35.5
Current
6%
Cheaper
vs 3-y average of 37.7

Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.

P/FCFE
35.5
=
Market Cap
¥8.8B
/
Free Cash Flow to Equity
¥252.8m

Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.

P/FCFE
35.5
=
Market Cap
¥8.8B
/
Free Cash Flow to Equity
¥252.8m

Valuation Scenarios

Shanghai Haohai Biological Technology Co Ltd is trading below its 3-year average

If P/FCFE returns to its 3-Year Average (37.7), the stock would be worth ¥42.11 (6% upside from current price).

Statistics
Positive Scenarios
3/4
Maximum Downside
-26%
Maximum Upside
+59%
Average Upside
15%
Scenario P/FCFE Value Implied Price Upside/Downside
Current Multiple 35.5 ¥39.65
0%
3-Year Average 37.7 ¥42.11
+6%
5-Year Average 42.4 ¥47.4
+20%
Industry Average 56.2 ¥62.86
+59%
Country Average 26.4 ¥29.51
-26%

Forward P/FCFE
Today’s price vs future free cash flow to equity

Not enough data available to calculate forward P/FCFE

Peer Comparison

All Multiples
P/FCFE
P/E
All Countries
Close
Market Cap P/FCFE P/E
CN
Shanghai Haohai Biological Technology Co Ltd
SSE:688366
9B CNY 35.5 35.7
FR
Pharnext SCA
OTC:PNEXF
6T USD -2 855 158.7 -160 127.7
US
Abbvie Inc
NYSE:ABBV
365.2B USD 23.4 87.3
US
Amgen Inc
NASDAQ:AMGN
178.1B USD 20.7 22.8
US
Gilead Sciences Inc
NASDAQ:GILD
163.4B USD 24.2 19.2
US
Epizyme Inc
F:EPE
94.1B EUR -480.6 -533.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
107.7B USD 33.9 27.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
74.1B USD 19.9 16.5
NL
argenx SE
XBRU:ARGX
41.3B EUR 159.6 37.4
US
Seagen Inc
F:SGT
39.3B EUR -66.1 -61.8
AU
CSL Ltd
ASX:CSL
60.2B AUD 35.5 29.5
P/E Multiple
Earnings Growth PEG
CN
Shanghai Haohai Biological Technology Co Ltd
SSE:688366
Average P/E: 34.4
35.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
87.3
97%
0.9
US
Amgen Inc
NASDAQ:AMGN
22.8
20%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
19.2
16%
1.2
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.2
19%
1.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.5
14%
1.2
NL
argenx SE
XBRU:ARGX
37.4
30%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
AU
CSL Ltd
ASX:CSL
29.5
9%
3.3

Market Distribution

In line with most companies in China
Percentile
60th
Based on 5 086 companies
60th percentile
35.5
Low
0.2 — 13.7
Typical Range
13.7 — 52.8
High
52.8 —
Distribution Statistics
China
Min 0.2
30th Percentile 13.7
Median 26.4
70th Percentile 52.8
Max 2 279 450.9

Shanghai Haohai Biological Technology Co Ltd
Glance View

Market Cap
9.1B CNY
Industry
Biotechnology

Shanghai Haohai Biological Technology Co., Ltd. operates at the cutting edge of the biopharmaceutical industry, specializing in regenerative medicine, medical aesthetics, and other biotechnology applications. Founded on the principles of innovation and science-driven solutions, the company has built an impressive portfolio that underscores its expertise in biological materials. Core to its operations is the development and commercialization of hyaluronic acid products, pivotal in fields such as ophthalmology, wound care, and more recently, dermal fillers for aesthetic treatments. Haohai Biological leverages high-end biotechnological processes to produce its offerings, ensuring that they meet the highest standards of quality and efficacy—a strategy that has allowed it to capture significant market share both domestically within China and beyond its borders. The revenue streams of Haohai Biological are as diversified as its product lines. The company generates income primarily through the sale of its high-margin pharmaceutical and medical device products. It has strategically positioned itself in the burgeoning market for medical aesthetics, where demand for cosmetic enhancements is rapidly growing, fueled by a global shift toward non-invasive procedures. Additionally, its ophthalmic products, crucial for surgeries and various ocular conditions, continue to be significant revenue drivers. Beyond product sales, Haohai invests in licensing its technologies and forging strategic partnerships with international firms, further enhancing its market reach and capitalizing on global biotechnology trends. This multifaceted approach positions the company not only as a producer but as a leader in scientific innovation and commercialization in the biotechnology sector.

Intrinsic Value
55.24 CNY
Undervaluation 28%
Intrinsic Value
Price ¥39.65
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett